- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01580878
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
May 3, 2017 updated by: Taro Pharmaceuticals USA
A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis.
The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with interdigital tinea pedis.
It will also be determined whether the efficacy of each of the two active treatments is superior to that of the vehicle cream (placebo).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
707
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing & able to provide & understand written informed consent
- Healthy male or non-pregnant, non-lactating female at least 18 years of age and older
- Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or that is predominantly interdigital but may extend to other areas
- Tinea pedis provisionally confirmed at baseline by positive potassium hydroxide (KOH)wet mount preparation showing segmented fungal hyphae
- Has sum of the clinical signs and symptoms scores of the target lesion of at least 4, including a minimum score of 2 for erythema & a minimum score of 2 for scaling or pruritus
- Currently in general good health with no clinically significant disease
- Willing and able to understand and comply with study requirements
- Women of childbearing potential must have a negative urine pregnancy test and be willing to use an acceptable form of birth control during study
Exclusion Criteria:
- Females who are pregnant, breastfeeding, planning a pregnancy, or do not agree to use an acceptable form of birth control during the study
- Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface
- Presence of any other infection of the foot or other disease that might confound treatment evaluation
- History of dermatophyte infections unresponsive to antifungal drugs
- Known hypersensitivity to Butenafine Hydrochloride or any component of the study medications
- Use of antipruritics, topical systemic corticosteroid, antibiotic or antifungal therapy, oral terbinafine or itraconazole, or immunosuppressive medication or radiation therapy more recently than indicated washout period
- Current oral, vaginal, or mucocutaneous candidiasis
- Current bacterial skin infection, secondary cellulitis, lymphangitis, or pyoderma
- Presence of current conditions that require systemic antimicrobial or antifungal therapy
- Uncontrolled diabetes mellitus, peripheral vascular disease, chronic venous stasis, or other significant condition
- Current severe onychomycosis
- Any clinically significant condition or situation, other than condition being studied, that would interfere with the study evaluations or participation
- Use of any investigational drugs or device within 30 days of signing Informed Consent Form (ICF)
- Current participation in any other clinical study
- Consumes excessive amounts of alcohol, abuses drugs, or has any condition that would compromise compliance
- Previous participation in this study
- Subjects with past history of tinea pedis with lack of response to antifungal therapy
- Subjects who in Investigator's opinion would be non-compliant
- Employees or direct relatives of an employee of the study center or Investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Butenafine Hydrochloride Cream, 1%
Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
|
Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
|
Active Comparator: Lotrimin Ultra®
Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
|
Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
|
Placebo Comparator: Butenafine Vehicle
Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
|
Butenafine Vehicle applied twice daily for 7 consecutive days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Therapeutic Cure
Time Frame: 42 days
|
Subjects with both clinical cure and mycologic cure are considered therapeutic cures.
|
42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
April 17, 2012
First Submitted That Met QC Criteria
April 18, 2012
First Posted (Estimate)
April 19, 2012
Study Record Updates
Last Update Posted (Actual)
May 5, 2017
Last Update Submitted That Met QC Criteria
May 3, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Foot Diseases
- Bacterial Infections and Mycoses
- Skin Diseases, Infectious
- Mycoses
- Skin Manifestations
- Dermatomycoses
- Foot Dermatoses
- Pruritus
- Tinea
- Tinea Pedis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Clotrimazole
- Butenafine
Other Study ID Numbers
- BTNF 1104
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinea Pedis
-
National institute of SiddhaCompletedTinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are StudiedIndia
-
Taro Pharmaceuticals USATerminated
-
DermBiont, Inc.TerminatedInterdigital Tinea PedisDominican Republic
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedInterdigital Tinea PedisUnited States
-
Ahmed A. H. AbdellatifUnknownFoot Infection Tinea PedisEgypt
-
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...CompletedOnychomycosis/Onycholysis and Tinea PedisUnited States
-
Tinea PharmaceuticalsCompletedTinea Pedis | Tinea Cruris | Tinea CorporisUnited States, Puerto Rico, El Salvador, Belize, Honduras
-
Therapeutics, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch & Lomb IncorporatedBausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisDominican Republic, Honduras
Clinical Trials on Butenafine Hydrochloride Cream, 1%
-
Taro Pharmaceuticals USATerminated
-
Shanghai Zhongshan HospitalUnknownPortal Vein PressureChina
-
BayerCompleted
-
BayerCompleted
-
United LaboratoriesUnknown
-
Betta Pharmaceuticals Co., Ltd.Quintiles, Inc.Completed
-
BayerCompleted
-
Taro Pharmaceuticals USACompletedTinea PedisUnited States, Belize
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdCompleted
-
BayerCompletedDermatitis, PhotoallergicUnited States